Dallas, Texas 04/03/2014 (FINANCIALSTRENDS) – iShares NASDAQ Biotechnology Index (ETF) (NASDAQ:IBB) has been on the top for quite a long time now and recently has taken a U-turn and is heading on a downward spiral. This sudden fall was seen after 17th March when the Democrats' who were attending the...
Aducanumab, a clinical treatment drug, primed to treat those with early symptoms of Alzheimer’s, recently went into Phase 1B clinical studies trial. Recently, the firm responsible for the manufacturing of the clinical treatment drugs, Biogen Inc. (NASDAQ:BIIB) released the data obtained from the Phase 1B trial. The data will be...
Lets take a close look at () today to get a better sense of the company and its current status, as well as the opportunity it may offer for prospective investors. Today's focus will be a fundamental evaluation of the stock from top to bottom. As such, let's start with...
Dallas, Texas 04/28/2014 (FINANCIALSTRENDS) – Prana Biotechnology Limited (ADR)(NASDAQ:PRAN) has in the past week announced the results of the top-line results after the company declared its ‘12-month Phase II imaging trails’ as part of its Alzheimer’s disease solution matrix. With several companies vying for top drug or therapy to resolve age-related problems...
Although a tremendous progress has been made, large full-thickness skin defects are still associated with mortality due to a low availability of donor skin areas. Autologous cultured epidermal autografts (CEA) were first to be used as an epidermal substitute; however, their functional and esthetic results were unsatisfying due to graft...
May 06, 2015 OTC Disclosure & News Service - SILVER SPRING, Md., May 6, 2015 (GLOBE NEWSWIRE) -- PharmaCyte Biotech, Inc. (OTCQB:PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today announced that the Institute of Virology at the...
Shares of (NASDAQ:) are currently up by more than from the open today and are trading at $. More than shares have exchanged hands compared to an average trading volume of . At the current pps, the market cap stands at $. The stock prices of...
Shares of (NASDAQ:) are currently up by more than from the open today and are trading at $. More than shares have exchanged hands compared to an average trading volume of . At the current pps, the market cap stands at $. The stock prices of...
Shares of (NASDAQ:) are currently up by more than from the open today and are trading at $. More than shares have exchanged hands compared to an average trading volume of . At the current pps, the market cap stands at $. The stock prices of...
Conatus Pharmaceuticals Inc (NASDAQ:CNAT) inked an alliance agreement with Novartis for development of their lead product, a drug called emricasan. The transaction was done with an upfront cost of $50 million and around $650 million to be paid in milestone payments in the times to come. Novartis gets emricasan’s rights...